Skip to main content
Equibles
RIGL logo

RIGL · Rigel Pharmaceuticals Inc

Track RIGL — free

Use RIGL with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about RIGL

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$45.25 -1.71 (-3.64%) At close · Aug 20
Market Cap
$851.71M
Shares
18.68M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$45.25 Open$46.24 Day$44.80–47.34 52W close$25.44–50.96 Avg vol 30d333K Short int3.1M · 16.6% float · 10.6d Short vol70% Last earningsAug 4, 2026 DataJun 2024–Aug 2026 Filing10-Q · Aug 4

Raw chart and full-history price indicators begin at the captured split on Jun 27, 2024; bars on opposite sides are not compared.

Up next

Next earnings call
Nov 3, 2026 Est · unconfirmed · in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 4, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
      Market backdrop VIX 14.9 · calm Equity put/call 0.52
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +26%
      above
      Price vs 50-day avg +16%
      above
      RSI (14) 65
      neutral
      MACD trend Positive
      52-week position 78%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Strong
      1-month return +23%
      trailing
      6-month return +30%
      trailing
      YTD return +6%
      this year
      Relative strength +19%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $39 › 200d $36 — 50d above 200d
      Institutional flow Distributing
      -1% holders QoQ · +26 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      16.56% of float · ▼ -2.0% MoM · 10.6 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      157 holders — mid 3-yr range
      Squeeze score 79
      high risk · 0–100
      Fundamentals
      Excellent
      Revenue growth +64%
      Y/Y
      EPS growth +1868%
      Y/Y
      Free cash flow $75.2M
      Valuation P/E 2.7
      below peers
      Balance sheet $11.9M
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 66%
      annualized · 1-yr
      Max drawdown −50%
      past year
      ATR 4.7%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed Aug 4, 2026
      Total revenues · 2026 $285M – $295M
      prior FY $294.28M midpoint −1.5% Y/Y
      Net product sales, excluding VEPPANU · 2026 $255M – $265M
      Net product sales · 2026 $255M – $265M
      Prior guidance period ended · from the 8-K filed Nov 4, 2025
      Total revenue · full year 2025 $285M – $290M
      Guided vs delivered · last 1 settled
      Total revenue full year 2025
      guided $285M – $290M
      $294.28M Beat +2.4%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      0 · 4 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +26% Bullish
      Price vs 50-day avg
      +16% Bullish
      RSI (14)
      65 Neutral
      MACD trend
      Positive Bullish
      52-week position
      78% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $39 › 200d $36 — 50d above 200d
      Institutional flow Distributing
      -1% holders QoQ · +26 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      16.56% of float · ▼ -2.0% MoM · 10.6 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      157 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $25 Now $45 · 78% Range high $51
      vs 200-day avg +26% vs 50-day avg +16%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      GAVRETO net product sales $20.3M six months ended June 30, 2026 —
      REZLIDHIA net product sales $17M six months ended June 30, 2026 —
      TAVALISSE net product sales $84.7M six months ended June 30, 2026 —
      cash, cash equivalents, and short-term investments $154.6M as of December 31, 2025 —
      full-year net product sales growth 60% full year 2025 —
      RBC-TI (>=8 weeks) in evaluable transfusion dependent patients receiving R289 doses >=500 mg QD 33% Phase 1b dose escalation phase —
      RBC-TI in 500 mg BID dose group 40% Phase 1b dose escalation phase —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      RIGL
      Rigel Pharmaceuticals Inc
      this stock
      		$851.71M +5.7% +64.1% 2.7 16.6%
      ONC
      BeOne Medicines Ltd.
      		 $557.05B +21.5% +22179.2% 856.5 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $136.93B +19.2% +46.2% 31.5 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $86.39B +7.1% +20.8% 20.8 3.3%
      MRNA
      Moderna, Inc.
      		 $69.62B +352.1% +4.3% — 12.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      157
      % held
      88.5%
      Net QoQ
      +411.1K sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      219
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      3.1M
      Days to cover
      10.6d
      Change
      -64.6K sh
      View
      Short Volume
      Short vol %
      70%
      As of
      Aug 20, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      216
      Value
      $8.3K
      As of
      Jul 29, 2026
      View
      Off-Exchange
      Off-exchange %
      39.9%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $294.3M
      Net income (FY)
      $367.0M
      EPS diluted
      $19.48
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 4, 2026
      This year
      16
      View
      Proposed Sales
      Value
      $87.5K
      Shares
      2.5K
      Filed
      Jun 22, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 13, 2026
      View

      Performance

      Raw-price comparisons begin at the captured split on Jun 27, 2024; windows that need an earlier baseline remain unavailable.

      5D 20D 120D MTD YTD
      RIGL +10.9% +22.9% +30.3% +22.9% +5.7%
      SPY -2.0% +3.3% +11.2% +2.1% +11.8%
      vs SPY +12.9% +19.6% +19.1% +20.9% -6.2%
      Key facts CIK 1034842 CUSIP 766559702 13F (30d) 147 filings 146 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)